医学
肾脏疾病
内皮蛋白C受体
内科学
肾功能
免疫学
胃肠病学
血小板
凝血酶
作者
Qiyang Chen,Rimi Hazra,Danielle Crosby,Diane Lenhart,Shane C Lenhart,Paritosh Mondal,Yingze Zhang,Mehdi Nouraie,Roderick J. Tan,Charles T. Esmon,LV Rao,Kang Kim,Samit Ghosh
出处
期刊:Blood
[Elsevier BV]
日期:2024-05-31
卷期号:144 (5): 552-564
被引量:3
标识
DOI:10.1182/blood.2023023528
摘要
Chronic kidney disease (CKD) is a major contributor to morbidity and mortality in sickle cell disease (SCD). Anemia, induced by chronic persistent hemolysis, is associated with the progressive deterioration of renal health, resulting in CKD. Moreover, patients with SCD experience acute kidney injury (AKI), a risk factor for CKD, often during vaso-occlusive crisis associated with acute intravascular hemolysis. However, the mechanisms of hemolysis-driven pathogenesis of the AKI-to-CKD transition in SCD remain elusive. Here, we investigated the role of increased renovascular rarefaction and the resulting substantial loss of the vascular endothelial protein C receptor (EPCR) in the progressive deterioration of renal function in transgenic SCD mice. Multiple hemolytic events raised circulating levels of soluble EPCR (sEPCR), indicating loss of EPCR from the cell surface. Using bone marrow transplantation and super-resolution ultrasound imaging, we demonstrated that SCD mice overexpressing EPCR were protective against heme-induced CKD development. In a cohort of patients with SCD, plasma sEPCR was significantly higher in individuals with CKD than in those without CKD. This study concludes that multiple hemolytic events may trigger CKD in SCD through the gradual loss of renovascular EPCR. Thus, the restoration of EPCR may be a therapeutic target, and plasma sEPCR can be developed as a prognostic marker for sickle CKD.
科研通智能强力驱动
Strongly Powered by AbleSci AI